England’s SGLT2 inhibitor rollout still leaves large gaps in type 2 diabetes care
Prescribing of SGLT2 inhibitors has continued to rise in England after NICE broadened their recommended role in type 2 diabetes, yet the pattern of uptake shows a stubbornly uneven clinical response to guidance. In a population-based cross-sectional analysis of 587,826 people with T2DM, current prescribing on 1 September 2023 remained far from universal in the very groups for whom the drugs are now expected to deliver the greatest cardiometabolic benefit.
The most striking feature is the modest penetration into patients with established cardiovascular disease. Current use reached 19.5% in people with CVD, 29.4% in those with heart failure, and 30.5% in people with both CVD and heart failure. Among people classified as high cardiovascular risk and low cardiovascular risk, prescribing was 19.9% and 20.2%, respectively. Those figures suggest that the 2022 NICE update has not yet translated into broad, routine use across the full spectrum of eligible patients.
A one-sentence reality check follows from the data: most eligible patients were not receiving an SGLT2 inhibitor.
Cardiovascular disease, heart failure and the biology behind the prescribing gap
The February 2022 NICE update changed the therapeutic threshold by recommending that an SGLT2 inhibitor be offered to people with CVD or heart failure and considered for those at high cardiovascular risk. The rationale is clinically straightforward. These agents lower glucose, but their value in contemporary diabetes care extends beyond glycemic control, with established benefits in heart failure and cardiorenal disease pathways that make them especially attractive when vascular risk is already entrenched.
The prescribing pattern in this cohort suggests clinicians have responded more readily when heart failure is present than when cardiovascular disease exists without it. That pattern is biologically and operationally plausible. Heart failure has a visible day-to-day burden: edema, dyspnea, recurrent admissions, and a treatment culture that has already incorporated newer disease-modifying therapies. By contrast, stable atherosclerotic disease in diabetes can be managed conservatively for years, and the trigger to add a newer glucose-lowering agent may be less immediate even when vascular risk remains substantial.
Uptake was higher in people with more comorbidities in age-stratified analyses, reinforcing the idea that treatment intensity rises as the clinical picture becomes harder to ignore. In that setting, SGLT2 inhibitor use may be driven less by diabetes alone and more by the accumulation of complications that make guideline-concordant prescribing feel unavoidable.
Older adults, women, Black patients and deprived communities received less treatment
Adjusted analyses identified lower uptake in people aged over 60, women, Black people, and people living in areas of higher deprivation. These are not trivial subgroup differences. They point to the same fault lines that repeatedly appear across chronic disease care: age-related therapeutic caution, sex-based disparities in prescribing, ethnic inequities in access or treatment escalation, and structural barriers linked to deprivation.
In practical terms, lower prescribing in older adults may reflect concerns about volume depletion, polypharmacy, frailty, or reduced clinician appetite for adding another agent. Those concerns can be legitimate, but they also risk becoming a default brake on treatment even when the cardioprotective rationale is strong. In women, the lower uptake raises questions about whether cardiovascular risk is being weighted differently in prescribing decisions, or whether diabetes-related treatment intensification still lags behind risk accumulation in female patients.
Ethnic and socioeconomic differences deserve the most direct attention. A medicine that is intended to reduce cardiovascular and renal harm should not be distributed in a way that mirrors deprivation. Yet the adjusted model shows exactly that pattern. In a population this large, the signal is unlikely to be random noise. It implies that access, clinician behavior, service navigation, or patient-level barriers are interfering with equitable use of a therapy meant to close outcome gaps.
Prescribing was still low even where the indication is strongest
The low current prescribing rate in people with CVD but without heart failure is especially important. In many diabetes pathways, these are exactly the patients in whom the drug could offer meaningful vascular protection before the first major decompensation. If uptake stays near 20% in that group, the healthcare system is missing a large share of the preventive opportunity created by the guideline update.
This is where implementation matters more than pharmacology. The mechanism is already accepted: SGLT2 inhibition promotes glycosuria, natriuresis, and favorable hemodynamic and cardiorenal effects that fit the needs of patients with diabetes and established cardiovascular disease. The bottleneck is not proof of concept. The bottleneck is consistent execution in routine care, particularly outside the specialist settings where newer therapies tend to spread first.
What the England data say about guideline adoption 18 months on
The study used Clinical Practice Research Datalink records linked to hospital admissions, allowing investigators to evaluate prescribing across a very large real-world T2DM cohort on a fixed date after the NICE update had been in place for 18 months. Current prescription status was examined by cardiovascular risk category, chronic kidney disease status, age, gender, ethnicity, deprivation, and diabetes duration, with logistic regression used to assess adjusted associations.
That design captures implementation rather than trial efficacy. It does not ask whether SGLT2 inhibitors work; it asks how completely the health system has absorbed the recommendation to use them. The answer is mixed. Prescribing is rising, but the increase is not yet enough to call the policy shift mature. A large share of patients who appear to meet the updated criteria still were not receiving treatment, and the inequities in uptake indicate that diffusion has been uneven across patient groups.
The data also create a useful contrast between intention and delivery. NICE guidance broadened eligibility; clinical behavior has partially followed; population coverage still lags behind what the risk profile of these patients would justify. In a disease where cardiovascular and renal complications account for much of the long-term harm, every missed prescription represents more than a paperwork failure. It is a missed chance to alter trajectory.
The next step is not new evidence, but better implementation
The study ends with a clear implementation problem rather than a knowledge gap about efficacy. Prescribing continues to rise in England, but lower uptake in people with CVD without heart failure, women, Black patients, older adults, and those in more deprived areas points to an urgent need for targeted action. The most relevant unanswered practical question is how quickly primary care and diabetes services can normalize SGLT2 inhibitor prescribing in the exact groups the guidance was written to serve.
Until that happens, the main limitation is not the absence of a treatment option. It is the uneven reach of a proven one.